<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="4878">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 08, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04606407</url>
  </required_header>
  <id_info>
    <org_study_id>BA_VPLF_01</org_study_id>
    <nct_id>NCT04606407</nct_id>
  </id_info>
  <brief_title>Inhaled NO for the Treatment of Viral Pneumonia in Adults</brief_title>
  <official_title>Prospective, Open-label, Randomized, Multi-Center Study for Safety and Efficacy Evaluation of Inhaled Nitric Oxide (NO) Given Intermittently to Adults With Viral Pneumonia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Beyond Air Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Beyond Air Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>Yes</is_unapproved_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this multi center, open label, randomized, study is to obtain information on&#xD;
      the safety and efficacy of 150 ppm Nitric Oxide given in addition to the standard of care of&#xD;
      patients with viral pneumonia&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 25, 2020</start_date>
  <completion_date type="Anticipated">September 7, 2021</completion_date>
  <primary_completion_date type="Anticipated">September 7, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>incidence of Serious Adverse Events</measure>
    <time_frame>30 days</time_frame>
    <description>Clinical safety will be assessed by incidence of Serious Adverse Events (SAEs)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>fever resolution</measure>
    <time_frame>Baseline to 30 days</time_frame>
    <description>Time to fever resolution</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ICU admission</measure>
    <time_frame>Baseline to 30 days</time_frame>
    <description>Number of patients requiring admission to ICU</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Oxygen support</measure>
    <time_frame>Baseline to 30 days</time_frame>
    <description>Time until patient no longer requires supportive oxygen</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stable room air saturation</measure>
    <time_frame>Baseline to 30 days</time_frame>
    <description>b.d. Stable room air saturation of 93% and above or returning to baseline saturation, whichever is lower</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">90</enrollment>
  <condition>Viral Pneumonia</condition>
  <condition>Nitric Oxide</condition>
  <condition>Respiratory Disease</condition>
  <condition>Pneumonia, Viral</condition>
  <condition>Inhaled Nitric Oxide</condition>
  <condition>Covid19</condition>
  <condition>SARS-CoV Infection</condition>
  <arm_group>
    <arm_group_label>Treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Inhaled NO delivered using LungFit™ in addition to standard of care</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard of care</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Standard of care</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>LungFit™</intervention_name>
    <description>Patients will receive inhalations of 150 ppm for 40 min 4 times a day, up to 7 days (maximum 28 treatments)</description>
    <arm_group_label>Treatment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients (male and female) admitted to the hospital for viral pneumonia and found&#xD;
             positive for viral infection via nasal swab&#xD;
&#xD;
          -  Age 18 to 80 years&#xD;
&#xD;
          -  Female subjects must be willing to use medically acceptable contraception from&#xD;
             screening to Day 30 (acceptable forms of contraception: abstinence, hormonal birth&#xD;
             control, intrauterine device, or barrier method plus a spermicidal agent).&#xD;
&#xD;
          -  Ability to understand and comply with study requirements.&#xD;
&#xD;
          -  Signed informed consent by subject&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients who are treated with or require high flow nasal cannula, CPAP, intubation,&#xD;
             mechanical ventilation, or tracheostomy&#xD;
&#xD;
          -  Breastfeeding or pregnancy as evidenced by a positive pregnancy test.&#xD;
&#xD;
          -  Subjects diagnosed with immunodeficiency, with history of congestive or unstable heart&#xD;
             disease, left ventricular dysfunction (LVEF &lt;40%) or myocardial damage, severe&#xD;
             pulmonary hypertension and/or unstable hypertension&#xD;
&#xD;
          -  Use of an investigational drug during the last 30 days prior enrollment&#xD;
&#xD;
          -  Methemoglobin level &gt;3% at screening&#xD;
&#xD;
          -  Patients on chronic (over two weeks of treatment) systemic steroids (any formulation,&#xD;
             excluding Dexamethasone) within 30 days prior to enrollment.&#xD;
&#xD;
          -  History of daily, continuous oxygen supplementation&#xD;
&#xD;
          -  Patients with BMI greater than or equal to 40&#xD;
&#xD;
          -  Patients with clinically significant anemia, e.g., Hb &lt;10.0 and/or thrombocytopenia,&#xD;
             e.g., Platelets &lt;75.&#xD;
&#xD;
          -  Smokers who are unwilling to refrain from smoking during hospitalization&#xD;
&#xD;
          -  Presence of a condition or abnormality that in the opinion of the Investigator would&#xD;
             compromise the safety of the subject or the quality of the data, e.g., known or&#xD;
             suspected thalassemia, sickle cell disease or other diseases associated with poor&#xD;
             oxygen carrying capacity.&#xD;
&#xD;
          -  The subject is identified by the investigator as being unable or unwilling to perform&#xD;
             study procedures.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Asher Tal</last_name>
    <role>Study Director</role>
    <affiliation>Beyond Air</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Meital Hatan</last_name>
    <phone>+972-8-6320060</phone>
    <email>mhatan@beyondair.net</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Rinat Kalaora</last_name>
    <email>rkalaora@beyondair.net</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Shaare Zedek Medical Center</name>
      <address>
        <city>Jerusalem</city>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Talya Wolak, Prof</last_name>
    </contact>
    <contact_backup>
      <last_name>Meital Bash</last_name>
    </contact_backup>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>October 22, 2020</study_first_submitted>
  <study_first_submitted_qc>October 27, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 28, 2020</study_first_posted>
  <last_update_submitted>December 2, 2020</last_update_submitted>
  <last_update_submitted_qc>December 2, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 3, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Inhaled Nitric Oxide</keyword>
  <keyword>iNO</keyword>
  <keyword>Virus</keyword>
  <keyword>Respiratory Disease</keyword>
  <keyword>Viral Pneumonia</keyword>
  <keyword>COVID-19</keyword>
  <keyword>SARS-CoV-2</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronavirus Infections</mesh_term>
    <mesh_term>Severe Acute Respiratory Syndrome</mesh_term>
    <mesh_term>Pneumonia, Viral</mesh_term>
    <mesh_term>Pneumonia</mesh_term>
    <mesh_term>Respiratory Aspiration</mesh_term>
    <mesh_term>Respiration Disorders</mesh_term>
    <mesh_term>Respiratory Tract Diseases</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

